ARID1A and cancer: ARID1A mutations increase the sensitivity of these cancer cells to GCLC depletion, indicating that targeting GCLC could selectively attack cancer cells while sparing normal cells, thereby reducing the risk of excessive ROS buildup and DNA damage (43).